Home-based subcutaneous immunoglobulin versus hospital-based intravenous immunoglobulin in treatment of primary antibody deficiencies: systematic review and meta analysis.
about
Health-related quality of life in patients with primary immunodeficiency diseaseAn update on the use of immunoglobulin for the treatment of immunodeficiency disordersExperience with Subgam, a Subcutaneously Administered Human Normal Immunoglobulin (ClinicalTrials.gov--NCT02247141)Intravenous and subcutaneous immunoglobulin replacement: a two-way road. Optimizing healthcare quality in patients with primary immunodeficiencies.Is dosing of therapeutic immunoglobulins optimal? A review of a three-decade long debate in europeCosts of Hospital Admission on Primary Immunodeficiency Diseases.Improving current immunoglobulin therapy for patients with primary immunodeficiency: quality of life and views on treatmentImplications to payers of switch from hospital-based intravenous immunoglobulin to home-based subcutaneous immunoglobulin therapy in patients with primary and secondary immunodeficiencies in Canada.II Brazilian Consensus on the use of human immunoglobulin in patients with primary immunodeficiencies.The optimal choice of medication administration route regarding intravenous, intramuscular, and subcutaneous injection.Subcutaneous Immunoglobulin Therapy in the Chronic Management of Myasthenia Gravis: A Retrospective Cohort Study.Use of subcutaneous immunoglobulin in primary immune deficiencies.Bioavailability of IgG administered by the subcutaneous route.Efficacy, safety, tolerability and pharmacokinetics of a novel human immune globulin subcutaneous, 20%: a Phase 2/3 study in Europe in patients with primary immunodeficiencies.Immunoglobulin therapy for refractory Crohn's disease.Increased Incidence of Fatigue in Patients with Primary Immunodeficiency Disorders: Prevalence and Associations Within the US Immunodeficiency Network Registry.A review on guidelines for management and treatment of common variable immunodeficiency.Subcutaneous immunoglobulin for primary and secondary immunodeficiencies: an evidence-based review.Subcutaneous immunoglobulin therapy for inflammatory neuropathy: current evidence base and future prospects.Intravenous versus Subcutaneous Drug Administration. Which Do Patients Prefer? A Systematic Review.Immunoglobulin replacement therapy for primary immunodeficiencies.Primary immunodeficiencies: a decade of shifting paradigms, the current status and the emergence of cutting-edge therapies and diagnostics.Different brands of intravenous immunoglobulin for primary immunodeficiencies: how to choose the best option for the patient?Clinical phenotype classification for selective immunoglobulin A deficiency.Managing patients with side effects and adverse events to immunoglobulin therapy.A cohort of French pediatric patients with primary immunodeficiencies: are patient preferences regarding replacement immunotherapy fulfilled in real-life conditions?Life with a Primary Immune Deficiency: a Systematic Synthesis of the Literature and Proposed Research Agenda.A Comparative Study of Intravenous Immunoglobulin and Subcutaneous Immunoglobulin in Adult Patients with Primary Immunodeficiency Diseases: A Systematic Review and Meta-Analysis.Clinical experiences in primary and secondary immunodeficiencies and immune-mediated conditions using Gammanorm(®).High dose subcutaneous immunoglobulin for idiopathic inflammatory myopathies and dysimmune peripheral chronic neuropathies treatment: observational study of quality of life and tolerance.Recombinant human hyaluronidase facilitated subcutaneous immunoglobulin treatment in pediatric patients with primary immunodeficiencies: long-term efficacy, safety and tolerability.Facilitated subcutaneous immunoglobulin administration (fSCIg): a new treatment option for patients with secondary immune deficiencies.Antibody levels to Bordetella pertussis and Neisseria meningitidis in immunodeficient patients receiving immunoglobulin replacement therapy.Long-term evaluation of a historical cohort of Iranian common variable immunodeficiency patients.Quality of Life, Treatment Beliefs, and Treatment Satisfaction in Children Treated for Primary Immunodeficiency with SCIg.Primary immunodeficiency disorders in Iran: update and new insights from the third report of the national registry.Economic burden of common variable immunodeficiency: annual cost of disease.In-depth interviews of patients with primary immunodeficiency who have experienced pump and rapid push subcutaneous infusions of immunoglobulins reveal new insights on their preference and expectations.Cost-effectiveness analysis of subcutaneous immunoglobulin replacement therapy in Iranian patients with primary immunodeficiencies.Rapid Push vs Pump-Infused Subcutaneous Immunoglobulin Treatment: a Randomized Crossover Study of Quality of Life in Primary Immunodeficiency Patients
P2860
Q26784167-6A1E90E4-DAEF-4E43-919D-AF4E23AE33B4Q27012785-2D919E38-D5DE-4E76-ACA6-218332DEB610Q28546873-540A18F9-9FB4-4EEA-BF00-92066731DF22Q33417506-98782A3B-C600-4508-AA66-FC3F0CB5CB05Q33419638-5FE7B2E0-299F-4FD1-82F5-F92B4E3A5EC3Q33575500-78097409-D6CC-4E7F-A648-EC97122765CAQ33583520-F33AE3DB-ADFF-4292-9923-1606654DCB5BQ33676857-A56A5BA6-A7F5-4EE4-8FDA-0770C43EE273Q33692418-1A1BD85F-1CC5-4008-87F0-E4B6F4592EBEQ35827701-F11CCA31-3977-462F-8E4D-20CAEDB6BFE0Q36094658-54164265-EF54-4BEB-BA66-D776D804BEF2Q36791300-753FCDEA-B451-49B6-A322-373766D540A0Q36927579-242C8F5B-2F71-4B7E-AFDF-5883643515ECQ37514512-61494C29-33BD-4843-AEA4-1176DB9B3B13Q37519134-2AD1B3DE-5E6D-46D2-9D61-46C116993B92Q37666847-307F210B-7406-4C05-A005-BC92F9FFCCC1Q38111423-5CA2C02C-9006-4F6E-89DF-E5AF0CAE0FE7Q38122120-86348C4C-7FFD-40E2-AA30-6E9866A05FA2Q38152428-7F113C20-6C58-4281-9DD0-A567DF69268BQ38228519-0594302B-069E-4CF0-B095-2904CF5F80E6Q38257643-6A1DB082-8F54-45EB-AB19-B6B5B6883D51Q38289442-5DCD70E6-0175-4871-B52B-17A9FC8F5131Q38569717-4BC9C867-FF4A-40A2-A9D0-53B94AD8223DQ38573627-5C835310-83B3-4A99-9D05-B0C1F7889C6EQ38614953-2F84982C-3F68-4B15-A29F-44A91BE78EA6Q38661420-12E5F63D-6C49-40FA-8244-0D2BCF3101E4Q38731981-543488A0-8D7D-431A-B9EB-97957F5BAB74Q38744512-747FB137-70EE-4F40-91E6-C734FB5C3CEDQ39217483-B79B130B-F2F9-468A-B669-DC4F5597DBE0Q39604919-026B8D6D-2791-4661-8A0C-1DA48D780565Q40596658-C14E0F7B-C44D-4BC8-A884-E83582B2A985Q40683402-8FC7C7EF-C991-452D-BEC4-34B0C3172986Q41516117-0D2E7CB8-6295-4121-B8AC-6FAF73107CB1Q41737545-F5B4D0A4-5FFD-4B42-9BD0-AB635429E3B6Q48302996-AFECF343-B74C-4169-A879-C126F6BB7B88Q51151956-47EDFDE6-44C8-43DB-93A6-38B6BD2BBF62Q51276222-119106BE-7BFA-489C-ABF3-753B2E3E2D6BQ52331721-E6182D18-3463-4FE2-B4D1-3F9CC60A7969Q55311044-E46011CB-2A6C-4B96-9D70-BF5EE9544A69Q57612649-96EC4A53-5644-4C9E-B758-E783E5B36035
P2860
Home-based subcutaneous immunoglobulin versus hospital-based intravenous immunoglobulin in treatment of primary antibody deficiencies: systematic review and meta analysis.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Home-based subcutaneous immuno ...... atic review and meta analysis.
@en
type
label
Home-based subcutaneous immuno ...... atic review and meta analysis.
@en
prefLabel
Home-based subcutaneous immuno ...... atic review and meta analysis.
@en
P2860
P50
P1476
Home-based subcutaneous immuno ...... atic review and meta analysis.
@en
P2093
Hans D Ochs
Mohammad Salehi Sadaghiani
P2860
P2888
P304
P356
10.1007/S10875-012-9720-1
P577
2012-06-23T00:00:00Z
P6179
1021591212